Christoph Oj Karch, MD
Neurology · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 22
- 5 carriers
- Office
- 1
Offices
1 location · County of Santa Clara · 1,000 clinicians in this group
Looking this up.
Hospitals listed: Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plans that list them
22 plans · 5 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Karch’s office at (408) 885-5000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
22 of 22 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A129008 · Current
Licensed to practise in California · since 2014 · expires 2027-09-30 · University of Luebeck Faculty of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$22,080
Medicare paid this office $22,080 for 170 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 47 | $7,033 | $150 |
| Critical care, first 30-74 minutes | 18 | $4,423 | $184 |
| Long return visit (40+ min) | 30 | $4,118 | $106 |
| Return visit (30+ min) | 41 | $2,639 | $55 |
| Telephone or internet assessment with verbal and written report by consulting physician, 21-30 minutes | 16 | $830 | $49 |
Who their Medicare patients are
170 Original Medicare patients in 2024. Average age 68 · Under 65 31% · 85 and older 11% · Women 48% · Also on Medicaid 76% · Health risk score 2.14. Above the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 71% · Diabetes 42% · Stroke 39% · Depression 29% · Chronic kidney disease 26% · Coronary heart disease 24% · Dementia 24% · Heart failure 22% · Atrial fibrillation 22% · COPD 15% · Cancer 12%.
The office billed $197,354, Medicare allowed $31,438 and paid $22,080; for 215 services of 19 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 170 | 215 | 68 | 2.14 | $197,354 | $22,080 |
| 2023 | 122 | 183 | 66 | 1.91 | $176,422 | $20,976 |
| 2022 | 119 | 164 | 67 | 1.69 | $130,489 | $17,663 |
| 2021 | 42 | 65 | 65 | 1.32 | $27,132 | $3,983 |
| 2019 | 73 | 101 | 68 | 2.21 | $75,566 | $8,552 |
| 2018 | 167 | 267 | 66 | 2.07 | $217,015 | $24,750 |
| 2017 | 147 | 219 | 65 | 1.78 | $155,658 | $16,831 |
| 2016 | 163 | 238 | 66 | 1.69 | $116,702 | $18,783 |
| 2015 | 49 | 100 | 71 | 1.31 | $39,174 | $5,965 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Critical care, first 30-74 minutes | 17 | $5,097 | $204 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $4,678 | $167 |
| Long return visit (40+ min) | 26 | $4,334 | $114 |
| Return visit (30+ min) | 44 | $3,774 | $66 |
2022: 5 services
| Critical care, first 30-74 minutes | 15 | $4,898 | $223 |
| Return visit (30+ min) | 51 | $4,559 | $76 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $4,038 | $213 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $1,414 | $109 |
| Telephone medical discussion with physician, 5-10 minutes | 12 | $400 | $27 |
2021: 3 services
| Return visit (30+ min) | 15 | $1,967 | $86 |
| Telephone medical discussion with physician, 11-20 minutes | 11 | $629 | $48 |
| Telephone medical discussion with physician, 5-10 minutes | 15 | $570 | $30 |
2019: 3 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $1,844 | $154 |
| Return visit (30+ min) | 35 | $1,560 | $40 |
| Telephone or internet assessment with verbal and written report by consulting physician, 21-30 minutes | 11 | $543 | $45 |
2018: 5 services
| Return visit (30+ min) | 87 | $7,484 | $56 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 25 | $4,455 | $171 |
| Critical care, first 30-74 minutes | 16 | $3,992 | $190 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 20 | $3,104 | $91 |
| New patient visit (60+ min) | 24 | $3,074 | $128 |
2017: 3 services
| Return visit (30+ min) | 79 | $6,426 | $57 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $1,496 | $93 |
| Long return visit (40+ min) | 23 | $1,433 | $62 |
2016: 6 services
| Return visit (30+ min) | 92 | $7,932 | $66 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,920 | $175 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $1,759 | $93 |
| Long return visit (40+ min) | 14 | $1,273 | $91 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 11 | $1,071 | $89 |
| Short return visit (20+ min) | 12 | $531 | $44 |
2015: 2 services
| Return visit (30+ min) | 20 | $1,353 | $64 |
| Test to measure expiratory airflow and volume | 21 | $153 | $7 |
Medicaid work
$10,406 in 2024
Medicaid paid $10,406 for 2,030 billed services this clinician did in 2024, up to 66 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 256 | $3,684 |
| Long return visit (40+ min) | 140 | $3,638 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 84 | $1,894 |
| IP/OBS CONSLTJ NEW/EST PT HIGH MDM 80 MINUTES | 49 | $1,190 |
| Pain severity quantified; no pain present (COA) (ONC) | 16 | $0 |
| Medication list documented in medical record (COA) | 400 | $0 |
| Review of all medications by a prescribing practitioner or clinical pharmacist (such as, prescriptions, OTCs, herbal therapies and supplements) documented in the medical record (COA) | 290 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 295 | $0 |
| Most recent systolic blood pressure 130-139 mm Hg (DM) (HTN, CKD, CAD) | 59 | $0 |
| Most recent systolic blood pressure greater than or equal to 140 mm Hg (HTN, CKD, CAD) (DM) | 28 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 284 | $0 |
| Most recent diastolic blood pressure 80-89 mm Hg (HTN, CKD, CAD) (DM) | 129 | $0 |
| 2024 | 2,030 | 12 | 66 | $10,406 |
| 2023 | 489 | 6 | 28 | $4,842 |
| 2022 | 224 | 3 | 52 | $2,523 |
| 2021 | 14 | 1 | 14 | $87 |
| 2019 | 76 | 1 | 39 | $426 |
| 2018 | 328 | 2 | 39 | $3,365 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 165 | $2,260 |
| Return visit (30+ min) | 271 | $2,131 |
| IP/OBS CONSLTJ NEW/EST PT HIGH MDM 80 MINUTES | 15 | $451 |
| Most recent hemoglobin A1c (HbA1c) level less than 7.0% (DM) | 13 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 13 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 12 | $0 |
2022
| Return visit (30+ min) | 182 | $1,458 |
| IP/OBS CONSLTJ NEW/EST PT HIGH MDM 80 MINUTES | 30 | $1,008 |
| Long return visit (40+ min) | 12 | $56 |
2021
| Return visit (30+ min) | 14 | $87 |
2019
| Return visit (30+ min) | 76 | $426 |
2018
| Return visit (30+ min) | 302 | $2,583 |
| IP/OBS CONSLTJ NEW/EST PT HIGH MDM 80 MINUTES | 26 | $782 |
Drugs they prescribed that Part D paid
$365,224
Pharmacies billed $365,224 in 2024. Most of that is one immune-globulin drugs at about $10,000 a fill for a small number of people.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,192) in 2024. At or below the middle of the specialty; the typical neurology clinician is at 0%.
1,096 generic and 75 brand-name prescriptions · $365,224 in drug cost · 15 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Privigen | Immune globulin | 16 | $154,590 | $9,662 |
| Keppra | None | 12 | $29,736 | $2,478 |
| Nurtec Odt | None | 11 | $10,731 | $976 |
| Levetiracetam | None | 150 | $8,942 | $60 |
| Dimethyl | None | 14 | $8,280 | $591 |
See all 29 drugs
| Privigen | Immune globulin | 16 | $154,590 | $9,662 |
| Keppra | None | 12 | $29,736 | $2,478 |
| Nurtec Odt | None | 11 | $10,731 | $976 |
| Levetiracetam | None | 150 | $8,942 | $60 |
| Dimethyl | None | 14 | $8,280 | $591 |
| Carbamazepine | None | 86 | $7,040 | $82 |
| Divalproex | None | 76 | $5,517 | $73 |
| Lacosamide | None | 77 | $5,516 | $72 |
| Oxcarbazepine | None | 46 | $3,732 | $81 |
| Mycophenolate Mofetil | None | 18 | $3,140 | $174 |
| Carbidopa-Levodopa | None | 48 | $2,141 | $45 |
| Pyridostigmine | None | 17 | $2,096 | $123 |
| Lamotrigine | None | 109 | $1,970 | $18 |
| Carbamazepine Er | None | 16 | $1,705 | $107 |
| Divalproex Sodium Er | None | 31 | $1,524 | $49 |
| Gabapentin | None | 74 | $1,330 | $18 |
| Zonisamide | None | 12 | $908 | $76 |
| Phenytoin Sodium Extended | None | 32 | $863 | $27 |
| Rivastigmine | None | 13 | $503 | $39 |
| Primidone | None | 25 | $500 | $20 |
| Prednisone | None | 14 | $340 | $24 |
| Phenobarbital | None | 21 | $319 | $15 |
| Topiramate | None | 19 | $303 | $16 |
| Pramipexole Dihydrochloride | None | 11 | $272 | $25 |
| Clonazepam | None | 28 | $234 | $8 |
| Nortriptyline | None | 13 | $177 | $14 |
| Pregabalin | None | 17 | $144 | $8 |
| Duloxetine | None | 13 | $120 | $9 |
| Lorazepam | None | 17 | $43 | $3 |
Year by year
| 2024 | 1,192 | 134 | 0% (0) | 6% | $365,224 |
| 2023 | 1,101 | 121 | 0% (0) | 9% | $465,613 |
| 2022 | 320 | 87 | 0% (0) | None | $113,984 |
| 2021 | 162 | 39 | 0% (0) | None | $48,701 |
| 2020 | 111 | 34 | 0% (0) | None | $8,963 |
| 2019 | 530 | 79 | 0% (0) | 8% | $114,345 |
| 2018 | 726 | 102 | 0% (0) | 8% | $152,438 |
| 2017 | 813 | 126 | 0% (0) | 8% | $76,239 |
| 2016 | 1,018 | 173 | 0% (0) | 6% | $140,521 |
| 2015 | 53 | 31 | 0% (0) | None | $3,457 |
| 2013 | 14 | None | 0% (0) | None | $1,831 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 27 drugs
| Privigen | Immune globulin | 20 | $168,934 | $8,447 |
| Vimpat | None | 24 | $27,886 | $1,162 |
| Rufinamide | None | 13 | $20,163 | $1,551 |
| Lacosamide | None | 40 | $17,709 | $443 |
| Levetiracetam | None | 169 | $15,176 | $90 |
| Nurtec Odt | None | 12 | $14,100 | $1,175 |
| Mycophenolate Mofetil | None | 23 | $14,095 | $613 |
| Carbamazepine | None | 68 | $7,032 | $103 |
| Divalproex | None | 66 | $3,828 | $58 |
| Gabapentin | None | 83 | $3,575 | $43 |
| Lamotrigine | None | 111 | $3,318 | $30 |
| Carbidopa-Levodopa | None | 27 | $3,112 | $115 |
| Oxcarbazepine | None | 40 | $2,785 | $70 |
| Carbamazepine Er | None | 17 | $2,760 | $162 |
| Divalproex Sodium Er | None | 15 | $2,238 | $149 |
| Pyridostigmine | None | 13 | $2,210 | $170 |
| Phenytoin Sodium Extended | None | 32 | $2,041 | $64 |
| Clobazam | None | 17 | $1,469 | $86 |
| Topiramate | None | 26 | $817 | $31 |
| Primidone | None | 19 | $768 | $40 |
| Zonisamide | None | 13 | $729 | $56 |
| Nortriptyline | None | 13 | $637 | $49 |
| Clonazepam | None | 35 | $518 | $15 |
| Phenobarbital | None | 15 | $470 | $31 |
| Prednisone | None | 24 | $380 | $16 |
| Pregabalin | None | 14 | $334 | $24 |
| Lorazepam | None | 13 | $98 | $8 |
2022: 7 drugs
| Vimpat | 13 | $11,612 | $893 |
| Pyridostigmine | 13 | $3,205 | $247 |
| Levetiracetam | 49 | $2,909 | $59 |
| Carbamazepine | 19 | $2,565 | $135 |
| Gabapentin | 42 | $2,123 | $51 |
| Carbidopa-Levodopa | 19 | $1,093 | $58 |
| Lamotrigine | 22 | $558 | $25 |
2021: 6 drugs
| Vimpat | 17 | $12,396 | $729 |
| Levetiracetam | 26 | $2,900 | $112 |
| Pyridostigmine | 11 | $2,074 | $189 |
| Carbamazepine | 14 | $1,142 | $82 |
| Gabapentin | 25 | $247 | $10 |
| Prednisone | 11 | $169 | $15 |
2020: 3 drugs
| Levetiracetam | 31 | $2,100 | $68 |
| Oxcarbazepine | 11 | $1,060 | $96 |
| Carbidopa-Levodopa | 15 | $1,041 | $69 |
2019: 16 drugs
| Vimpat | None | 12 | $10,648 | $887 |
| Carbamazepine Er | None | 15 | $6,527 | $435 |
| Rytary | Parkinson's | 12 | $4,795 | $400 |
| Levetiracetam | None | 84 | $3,494 | $42 |
| Carbidopa-Levodopa | None | 71 | $3,112 | $44 |
| Dilantin | None | 19 | $2,578 | $136 |
| Amantadine | None | 17 | $1,924 | $113 |
| Oxcarbazepine | None | 15 | $1,528 | $102 |
| Carbamazepine | None | 21 | $1,438 | $68 |
| Gabapentin | None | 35 | $1,207 | $34 |
| Phenytoin Sodium Extended | None | 12 | $1,158 | $97 |
| Primidone | None | 22 | $907 | $41 |
| Lamotrigine | None | 45 | $731 | $16 |
| Phenobarbital | None | 16 | $669 | $42 |
| Divalproex | None | 20 | $445 | $22 |
| Prednisone | None | 18 | $236 | $13 |
2018: 22 drugs
| Vimpat | None | 14 | $11,750 | $839 |
| Carbamazepine Er | None | 27 | $9,527 | $353 |
| Rytary | Parkinson's | 17 | $4,295 | $253 |
| Carbidopa-Levodopa | None | 116 | $4,183 | $36 |
| Levetiracetam | None | 101 | $4,070 | $40 |
| Pyridostigmine | None | 12 | $3,758 | $313 |
| Dilantin | None | 21 | $2,316 | $110 |
| Phenytoin Sodium Extended | None | 24 | $1,819 | $76 |
| Gabapentin | None | 28 | $1,149 | $41 |
| Phenobarbital | None | 24 | $1,097 | $46 |
| Zonisamide | None | 18 | $955 | $53 |
| Oxcarbazepine | None | 13 | $883 | $68 |
| Lamotrigine | None | 52 | $809 | $16 |
| Carbamazepine | None | 19 | $751 | $40 |
| Valproic Acid | None | 17 | $631 | $37 |
| Primidone | None | 12 | $528 | $44 |
| Divalproex | None | 32 | $464 | $14 |
| Pramipexole Dihydrochloride | None | 16 | $305 | $19 |
| Topiramate | None | 16 | $304 | $19 |
| Prednisone | None | 13 | $186 | $14 |
| Clonazepam | None | 18 | $94 | $5 |
| Mirtazapine | None | 12 | $70 | $6 |
2017: 22 drugs
| Vimpat | None | 13 | $10,240 | $788 |
| Carbidopa-Levodopa | None | 108 | $6,440 | $60 |
| Entacapone | None | 12 | $4,739 | $395 |
| Carbamazepine | None | 27 | $3,072 | $114 |
| Levetiracetam | None | 107 | $2,870 | $27 |
| Phenytoin Sodium Extended | None | 39 | $2,160 | $55 |
| Dilantin | None | 13 | $1,991 | $153 |
| Rytary | Parkinson's | 12 | $1,806 | $150 |
| Carbidopa-Levodopa Er | None | 38 | $1,599 | $42 |
| Phenobarbital | None | 30 | $1,429 | $48 |
| Memantine | None | 12 | $1,318 | $110 |
| Divalproex | None | 38 | $817 | $21 |
| Lamotrigine | None | 53 | $713 | $13 |
| Gabapentin | None | 31 | $607 | $20 |
| Primidone | None | 13 | $489 | $38 |
| Zonisamide | None | 16 | $484 | $30 |
| Pramipexole Dihydrochloride | None | 20 | $416 | $21 |
| Topiramate | None | 24 | $404 | $17 |
| Donepezil | None | 14 | $148 | $11 |
| Olanzapine | None | 11 | $106 | $10 |
| Mirtazapine | None | 13 | $76 | $6 |
| Clonazepam | None | 12 | $50 | $4 |
2016: 25 drugs
| Tecfidera | 11 | $72,626 | $6,602 |
| Carbidopa-Levodopa | 113 | $4,918 | $44 |
| Divalproex Sodium Er | 12 | $3,550 | $296 |
| Levetiracetam | 123 | $3,314 | $27 |
| Carbamazepine | 39 | $3,287 | $84 |
| Dilantin | 17 | $1,767 | $104 |
| Phenytoin Sodium Extended | 43 | $1,506 | $35 |
| Divalproex | 42 | $1,120 | $27 |
| Propranolol | 39 | $1,049 | $27 |
| Carbidopa-Levodopa Er | 20 | $1,035 | $52 |
| Oxcarbazepine | 17 | $1,018 | $60 |
| Gabapentin | 56 | $913 | $16 |
| Phenobarbital | 17 | $878 | $52 |
| Lamotrigine | 62 | $563 | $9 |
| Zonisamide | 17 | $506 | $30 |
| Baclofen | 20 | $486 | $24 |
| Topiramate | 35 | $444 | $13 |
| Memantine | 12 | $430 | $36 |
| Pramipexole Dihydrochloride | 24 | $425 | $18 |
| Diazepam | 13 | $306 | $24 |
| Donepezil | 20 | $206 | $10 |
| Primidone | 15 | $164 | $11 |
| Clonazepam | 43 | $155 | $4 |
| Olanzapine | 17 | $127 | $7 |
| Nortriptyline | 12 | $90 | $8 |
Money from drug and device companies
$40 in 2019
A payment is not proof that care is biased.
| Mitsubishi Tanabe Pharma America | None | $40 | 1 payment
|
See the published payment
| Mitsubishi Tanabe Pharma America | Education · 2019-01-21 | None | $40 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 80.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1629396684
- Licence
- CA A129008California A129008: Current · expires 2027-09-30
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2084N0008X (2084N0008X)
- Mailing address
- 751 S Bascom Ave, San Jose, CA, 95128
- NPI first listed
- 2010-05-13
- NPI last updated
- 2015-10-30
This is when the NPI record was last certified, not a medical board exam.